Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

In this online CME-certified program, experts discuss best practices and emerging strategies in CAR T-cell therapy for patients with leukemia, lymphoma, and myeloma. Watch the on-demand Webcast, download the slides from a dynamic CCO symposium in Orlando, and read expert commentaries to learn more about how to integrate CAR T-cells into your clinical practice.
person default
Stephen J. Schuster, MD

ClinicalThought

Review my approach to CAR T-cell therapy—including considerations for patient candidacy and managing toxicities—illustrated with a patient case from my practice.

person default Stephen J. Schuster, MD Released: October 17, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation
Kite, A Gilead Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?